Evidence map›Paper›PMID 32573903›Full record

SynthesisDiabetes, obesity & metabolism2020

Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis.

Awadhesh K Singh, Clare L Gillies, Ritu Singh, Akriti Singh, Yogini Chudasama, Briana Coles, Sam Seidu, Francesco Zaccardi, Melanie J Davies, Kamlesh Khunti

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Diabetes, obesity & metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 265 papers, 20 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
265citing papers in PubMed, 20 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

265 citing papers in PubMed, 20 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. COVID-19 and solid organ transplantation: Finding the right balance.Transplantation reviews (Orlando, Fla.) · 2022
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

205 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Awadhesh K SinghGD Hospital & Diabetes Institute, Kolkata, India.ORCID 0000-0002-8374-4536
Clare L GilliesLeicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.ORCID 0000-0002-8417-9700
Ritu SinghGD Hospital & Diabetes Institute, Kolkata, India.
Akriti SinghCollege of Medicine and JNM Hospital, Kalyani, Nadia, West Bengal, India.
Yogini ChudasamaLeicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.
Briana ColesLeicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.
Sam SeiduLeicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.ORCID 0000-0002-8335-7018
Francesco ZaccardiLeicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.
Melanie J DaviesNational Institute for Health Research (NIHR) Applied Research Collaboration - East Midlands (ARC-EM), Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK.ORCID 0000-0002-9987-9371
Kamlesh KhuntiLeicester Real World Evidence Unit, Leicester Diabetes Centre, Leicester, UK.

Funding

National Institute for Health Research
6 · The paper itself

Abstract

aimTo estimate the prevalence of both cardiometabolic and other co-morbidities in patients with COVID-19, and to estimate the increased risk of severity of disease and mortality in people with co-morbidities. MATERIALS AND

methodsMedline, Scopus and the World Health Organization website were searched for global research on COVID-19 conducted from January 2019 up to 23 April 2020. Study inclusion was restricted to English language publications, original articles that reported the prevalence of co-morbidities in individuals with COVID-19, and case series including more than 10 patients. Eighteen studies were selected for inclusion. Data were analysed using random effects meta-analysis models.

resultsEighteen studies with a total of 14 558 individuals were identified. The pooled prevalence for co-morbidities in patients with COVID-19 disease was 22.9% (95% CI: 15.8 to 29.9) for hypertension, 11.5% (9.7 to 13.4) for diabetes, and 9.7% (6.8 to 12.6) for cardiovascular disease (CVD). For chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), cerebrovascular disease and cancer, the pooled prevalences were all less than 4%. With the exception of cerebrovascular disease, all the other co-morbidities presented a significantly increased risk for having severe COVID-19. In addition, the risk of mortality was significantly increased in individuals with CVD, COPD, CKD, cerebrovascular disease and cancer.

conclusionsIn individuals with COVID-19, the presence of co-morbidities (both cardiometabolic and other) is associated with a higher risk of severe COVID-19 and mortality. These findings have important implications for public health with regard to risk stratification and future planning.

Indexed as

Cardiovascular DiseasesComorbidityCOVID-19Diabetes ComplicationsDiabetes MellitusHumansHypertensionMortalityNeoplasmsPandemicsPrevalencePulmonary Disease, Chronic ObstructiveRenal Insufficiency, ChronicRisk FactorsSARS-CoV-2Severity of Illness Indexco-morbiditiescoronavirusCOVID-19meta-analysissystematic review

Identifiers

PMID32573903
PMCPMC7361304

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.